LOI, SARA
 Distribuzione geografica
Continente #
EU - Europa 213
AS - Asia 59
NA - Nord America 30
SA - Sud America 1
Totale 303
Nazione #
DE - Germania 165
US - Stati Uniti d'America 27
CN - Cina 20
SG - Singapore 19
ES - Italia 14
IT - Italia 8
GB - Regno Unito 7
ID - Indonesia 5
RU - Federazione Russa 4
HK - Hong Kong 3
IE - Irlanda 3
IN - India 3
JP - Giappone 3
KZ - Kazakistan 3
MX - Messico 3
SE - Svezia 3
FI - Finlandia 2
FR - Francia 2
VN - Vietnam 2
AT - Austria 1
BE - Belgio 1
CH - Svizzera 1
EC - Ecuador 1
GR - Grecia 1
KR - Corea 1
NL - Olanda 1
Totale 303
Città #
Frankfurt am Main 160
Singapore 14
Madrid 9
New York 5
Southend 4
Almaty 3
Council Bluffs 3
Dublin 3
Jakarta 3
Milan 3
Xochimilco 3
Ashburn 2
Beijing 2
Helsinki 2
Ho Chi Minh City 2
Nanjing 2
Princeton 2
Terni 2
Athens 1
Bangalore 1
Baoding 1
Basel 1
Bengaluru 1
Central 1
Chicago 1
Chongqing 1
Düsseldorf 1
Fuzhou 1
Groningen 1
Guangzhou 1
Guiyang 1
Hiroshima 1
Hyderabad 1
Mannheim 1
Monza 1
Nuremberg 1
Oberursel 1
Oxford 1
Preston 1
Quito 1
Redwood City 1
Rho 1
Rome 1
Seoul 1
Somerville 1
Stockholm 1
Stockport 1
Tervuren 1
Toranomon 1
Tucson 1
Umeda 1
Vienna 1
Wilmington 1
Zunyi 1
Totale 260
Nome #
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis 138
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer 96
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC) 71
How future surgery will benefit from SARS-COV-2-related measures: a SPIGC survey conveying the perspective of Italian surgeons 12
Totale 317
Categoria #
all - tutte 771
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 771


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 7 0 0 1
2021/202213 0 0 3 0 1 2 0 2 1 3 0 1
2022/202333 1 1 7 5 1 6 0 0 0 3 7 2
2023/2024140 5 1 5 0 3 7 22 20 11 23 22 21
2024/2025123 19 21 15 15 10 5 5 20 13 0 0 0
Totale 317